Brief Summary
This study will investigate the effect Atezolizumab (Anti-PD-L1 Antibodya protein made by the immune system to fight against harmful substances (antigens), such as bacteria or viruses) Plus Bevacizumab (Anti-VEGF Antibody) Immunotherapya treatment that uses a person's immune system to fight cancer Before Surgical Resectionsurgical removal of tissue or part/all of an organ Versus Surgical Resection alone in Hepatocellular Carcinomacancer arising from tissues that line organs Patients.
Intervention/Treatment
- Drug: Atezolizumab (Tecentriq).
- Drug: Bevacizumab (Avastin).
- Surgical resection.
- Active surveillance.
Inclusion Criteria
- Signed Informed Consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment. Form.
- Age greater than or equal to 18 years.
- Ability to comply with the study protocol.
- First diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of HCC and MDT recommendation of curative resection.
- Absence of major macrovascular invasion.
- Absence of extrahepatic spread.
- AST and ALT less that or equal to 5 × upper limit of normal (ULN) and total bilirubin less than or equal to 51 µmol/L.
- Baseline FFPE tumoura tissue mass that forms from groups of unhealthy cells tissue biopsyremoval of a section of tissue to analyse for cancer cells.
- Documented virology status of hepatitis B and C.
- ECOG Performance Status of 0 or 1.
- Child-Pugh Class A status or up to B7.
- Adequate hematologic and end-organ function.